Beyond the Copy: Seven Indian Pharma Companies Quietly Rewriting the Rules of Drug Discovery for US Patients

The narrative is familiar and, to a considerable degree, accurate: India built its pharmaceutical reputation on the ability to manufacture high-quality medicines at a fraction of Western costs. Generic production remains the sector's commercial backbone. But reducing India's pharma landscape to that single dimension increasingly misrepresents what is happening inside its research and development laboratories.

Over the past decade, a meaningful cohort of Indian companies has committed substantial capital to novel drug discovery — original molecules, not reformulations. Their pipelines span oncology, immunology, rare genetic disorders, and infectious disease. Several have already secured US market approvals for genuinely new therapies. Others are in late-stage clinical trials with American patient populations enrolled. Taken together, they constitute an innovation story that the US healthcare community has been slow to fully register.

This feature profiles seven of those companies and the programs that deserve closer attention.

1. Biocon: From Enzymes to Biosimilars and Beyond

Bangalore-headquartered Biocon is perhaps the most internationally recognized name in Indian biopharmaceutical innovation, though its full scope remains underappreciated in US clinical circles. Founded in 1978 as an enzyme manufacturer, Biocon has evolved into a vertically integrated biologics developer with an FDA-approved biosimilar portfolio that includes trastuzumab (marketed as Ogivri in partnership with Mylan/Viatris) and bevacizumab — both targeting cancer indications where the originator biologics carry annual list prices exceeding $100,000.

More consequentially for the innovation narrative, Biocon's research division has been developing itacitinib, a selective JAK1 inhibitor, for acute graft-versus-host disease — a life-threatening complication following stem cell transplantation for which treatment options remain limited. The compound has progressed through Phase III evaluation, and its trajectory illustrates that Indian companies are capable of generating novel mechanism-of-action candidates, not merely replicating existing ones.

2. Sun Pharmaceutical Industries: Specialty Dermatology and Ophthalmology

Sun Pharma, India's largest pharmaceutical company by revenue, is well known in US generics markets. Less publicized is its specialty and innovative division, which has produced genuinely novel approvals for American patients.

Ilumya (tildrakizumab), an IL-23 inhibitor for moderate-to-severe plaque psoriasis, received FDA approval in 2018 — making Sun Pharma one of the very few Indian-origin companies to bring a first-in-class biologic to the US market. The compound was developed through Sun's acquisition of SPARC (Sun Pharma Advanced Research Company) and licensed to Almirall for European commercialization. In the US, Sun markets it directly, competing against established players including AbbVie and Novartis.

Sun's ophthalmic pipeline, developed partly through its acquisition of InSite Vision, also includes novel drug-device combination candidates for dry eye disease — a therapeutic area with substantial unmet need among aging American patients.

3. Dr. Reddy's Laboratories: Oncology and Proprietary Products

Dr. Reddy's Laboratories, headquartered in Hyderabad, has long maintained a proprietary products division alongside its generics business. Its differentiated portfolio includes DFD-29, a minocycline-based formulation for rosacea that received FDA approval in 2023 under the brand name Emrosi — a novel formulation development that the company advanced from its own research infrastructure.

In oncology, Dr. Reddy's has been active in developing liposomal and nanoparticle drug delivery systems intended to improve the therapeutic index of established cytotoxic agents. Its work on lipodox (a doxorubicin liposome formulation) and subsequent pipeline candidates reflects an understanding that delivery innovation can generate clinically meaningful differentiation even from known molecules — a strategy that has found traction with US oncology prescribers.

4. Zydus Lifesciences: Metabolic Disease and Novel Biologics

Ahmedabad-based Zydus Lifesciences made international headlines in 2021 when India's drug regulator granted emergency use authorization for ZyCov-D, the world's first plasmid DNA vaccine approved for human use — a platform technology with implications extending well beyond COVID-19.

For the US market, Zydus has been advancing Lipaglyn (saroglitazar), a dual PPAR alpha/gamma agonist developed entirely in-house for non-alcoholic steatohepatitis (NASH) and diabetic dyslipidemia. NASH represents one of the most significant unmet needs in hepatology, with no FDA-approved therapy available for the condition until very recently. Zydus's clinical data from Indian patient populations has informed its IND-enabling work for US Phase II trials, positioning saroglitazar as a genuine novel candidate in a commercially significant space.

The company's biologics division has additionally filed for US approval of pegylated interferon alpha-2b formulations and is developing novel monoclonal antibodies in immunology — investments that reflect a deliberate pivot toward science-driven value creation.

5. Cipla: Respiratory Innovation and Rare Pulmonary Disease

Cipla's global reputation was forged in the early 2000s when it offered triple antiretroviral therapy at a cost of one dollar per day, fundamentally altering the economics of HIV treatment in low-income countries. That humanitarian legacy, however, has sometimes obscured the company's technical innovation in respiratory drug delivery.

Cipla has developed proprietary inhalation technology platforms — including its Spiromax and Cirrus inhaler devices — that are under evaluation or approved in multiple markets. For the US, Cipla's partnership-driven approach has brought novel inhalation formulations of budesonide/formoterol and tiotropium through the FDA pathway.

More recently, Cipla has entered the rare pulmonary disease space with compounds targeting idiopathic pulmonary fibrosis (IPF), a progressive and ultimately fatal lung condition. With only two FDA-approved therapies currently available for IPF — nintedanib and pirfenidone — the condition represents an area of genuine unmet need. Cipla's pipeline activity in this space, while still in earlier developmental stages, signals an ambition that extends well beyond respiratory generics.

6. Glenmark Pharmaceuticals: Dermatology and Oncology Bispecifics

Mumbai-based Glenmark has constructed one of the more intriguing novel-molecule pipelines among Indian mid-cap pharma companies. Its innovation engine, operating under the subsidiary Ichnos Sciences (formerly Glenmark Immuno-Oncology), has focused on bispecific antibody platforms — a cutting-edge modality that simultaneously engages two distinct molecular targets.

ISB 1442, a bispecific antibody targeting CD38 and CD47 for relapsed/refractory multiple myeloma, has entered Phase I/II clinical evaluation in the United States. Multiple myeloma remains incurable for most patients, and the CD47 "don't eat me" signal represents a mechanistically novel approach to overcoming tumor immune evasion. US oncology centers including sites affiliated with academic medical centers are participating in the trial — a meaningful indicator of scientific credibility.

Glenmark's dermatology pipeline additionally includes novel TRPA1 antagonists for chronic pruritus, addressing a condition that disproportionately affects elderly patients and for which pharmacological options remain limited.

7. Mankind Pharma: Cardiovascular and Respiratory Novel Formulations

Mankind Pharma, one of India's fastest-growing pharmaceutical companies and a recent entrant to public markets, has been less visible in US innovation discussions — but its research investments in cardiovascular drug delivery and fixed-dose combination therapies are generating data sets with potential US relevance.

The company's work on novel nitrate formulations for heart failure management and its proprietary inhaler technology for asthma and COPD reflect an understanding that formulation science can deliver clinically meaningful advances. As Mankind expands its international regulatory filings, the US market represents a stated strategic priority.

What This Means for US Healthcare Stakeholders

For American physicians, formulary committees, and patient advocacy organizations, the emergence of Indian pharma companies as genuine innovators carries several practical implications.

First, competition in specialty and biologic markets — historically dominated by a small number of large Western companies — stands to intensify, with potential downward pressure on list prices. Second, the clinical trial networks being established by these companies are enrolling US patients, generating data in American populations that will inform prescribing decisions. Third, in therapeutic areas such as NASH, rare pulmonary disease, and hematologic malignancies — where unmet clinical need remains acute — Indian-origin compounds may represent meaningful additions to the treatment armamentarium.

The story of Indian pharmaceutical innovation is neither complete nor without its challenges. Clinical development timelines are long, regulatory pathways are demanding, and commercial execution in the US market requires capabilities that not every Indian company has yet fully developed. But the pipeline evidence is real, the regulatory submissions are filed, and the clinical trial investigators are enrolling.

PharmIndia Online will continue tracking these developments as they progress through the FDA review process and into American clinical practice. The conversation about what India contributes to US healthcare is overdue for a more complete telling.